IMATINIB MESYLATE
Clinical safety rating: avoid
Contraindicated (not allowed)
Mechanism information is still being processed. Check the DailyMed link in the sidebar for the official prescribing information.
Tablet 400 mg - Oral
Clinical note
Strong CYP3A4 inducers may decrease efficacy Can cause fluid retention and myelosuppression.
Fluid retention
Loading safety data…